• Partnership to Develop Gene Therapy Protocols

News & Views

Partnership to Develop Gene Therapy Protocols

Combinatorial cell culture technologies company Plasticell has signed an agreement with Sphere Fluidics to develop gene transduction protocols as alternatives to costly commercial transfection reagents currently used in gene therapy trials. Sphere Fluidics has developed high throughput single cell manipulation and screening technology in picoliter volumes. “A leading gene therapy approach involves the insertion of therapeutic genes into the genome of cells outside the body, followed by the administration of these cells into the patients to deliver the therapeutic gene product," said Dr Aaron Chuang, Plasticell’s CSO. “The efficiency, safety and cost of this process need to be optimised to ensure therapeutic efficacy, to mitigate potential adverse events such as insertional mutagenesis and to improve the cost-effectiveness of gene therapies.”

“Sphere Fluidics’ technology can potentially improve the current way of cell transduction and transfection. Our well controlled high-throughput approach can address some of the bottlenecks and risks of the cell manufacturing workflows. We are very keen to collaborate with Plasticell to investigate those issues, to optimise gene insertion processes and ultimately to improve the cell therapy efficacy,” added Dr Marian Rehak, Sphere Fluidics’ Director of R&D.


Digital Edition

LMUK 49.7 Nov 2024

November 2024

News - Research & Events News   - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...

View all digital editions

Events

analytica China

Nov 18 2024 Shanghai, China

Pharma Asia

Nov 20 2024 Karachi, Pakistan

Turkchem

Nov 27 2024 Istanbul, Turkey

Smart Factory Expo 2025

Jan 22 2025 Tokyo, Japan

Instrumentation Live

Jan 22 2025 Birmingham, UK

View all events